Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Ezetimibe added to statin therapy after acute coronary syndromes
IMPROVE-IT Investigators
Clinical Departments
Cardiology
Internal Medicine
Medicine Dean & Assoc. Deans
Harvard University
Duke University
University of Montreal
Vivantes Neukölln Medical Center
Carmel Medical Center
Canisius Wilhelmina Hospital
Leiden University
University of Pavia
Cardinal Stefan Wyszynski Institute of Cardiology
Merck
Research output
:
Contribution to journal
›
Article
›
peer-review
3518
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ezetimibe added to statin therapy after acute coronary syndromes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Coronary Syndrome
100%
Simvastatin
100%
Statin Therapy
100%
Ezetimibe
100%
Low-density Lipoprotein Cholesterol Level
57%
Monotherapy
42%
Lipid-lowering Therapy
28%
Placebo
14%
Adverse Effects
14%
Event Rate
14%
Double-blind Randomized Trial
14%
Cardiovascular Risk
14%
Confidence Interval
14%
Hazard Ratio
14%
Cardiovascular Mortality
14%
Cardiovascular Events
14%
Rehospitalization
14%
Low-density Lipoprotein Cholesterol (LDL-C)
14%
Stable Angina
14%
Median Time
14%
Kaplan-Meier
14%
Cardiovascular Outcomes
14%
Coronary Revascularization
14%
Gallbladder
14%
Nonfatal Myocardial Infarction
14%
Intestinal Cholesterol Absorption
14%
Nonfatal Stroke
14%
Absolute Risk Difference
14%
Time-weighted Average
14%
Non-statins
14%
Pharmacology, Toxicology and Pharmaceutical Science
Simvastatin
100%
Acute Coronary Syndrome
100%
Statin (Protein)
100%
Ezetimibe
100%
Low Density Lipoprotein Cholesterol
71%
Monotherapy
42%
Malignant Neoplasm
14%
Placebo
14%
Heart Infarction
14%
Adverse Event
14%
Unstable Angina Pectoris
14%